DE60239394D1 - Onkolytische virustherapie - Google Patents
Onkolytische virustherapieInfo
- Publication number
- DE60239394D1 DE60239394D1 DE60239394T DE60239394T DE60239394D1 DE 60239394 D1 DE60239394 D1 DE 60239394D1 DE 60239394 T DE60239394 T DE 60239394T DE 60239394 T DE60239394 T DE 60239394T DE 60239394 D1 DE60239394 D1 DE 60239394D1
- Authority
- DE
- Germany
- Prior art keywords
- oncolytic virus
- pharmaceutical composition
- virus therapy
- subject
- human leukocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 244000309459 oncolytic virus Species 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 210000000265 leukocyte Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29005101P | 2001-05-11 | 2001-05-11 | |
PCT/US2002/014642 WO2002091997A2 (en) | 2001-05-11 | 2002-05-09 | Oncolytic virus therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60239394D1 true DE60239394D1 (de) | 2011-04-21 |
Family
ID=23114328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60239394T Expired - Lifetime DE60239394D1 (de) | 2001-05-11 | 2002-05-09 | Onkolytische virustherapie |
Country Status (13)
Country | Link |
---|---|
US (3) | US7122182B2 (de) |
EP (1) | EP1385466B1 (de) |
JP (1) | JP4916641B2 (de) |
CN (1) | CN1332712C (de) |
AT (1) | ATE500808T1 (de) |
AU (1) | AU2002256510B2 (de) |
CA (1) | CA2442648C (de) |
DE (1) | DE60239394D1 (de) |
HU (1) | HUP0400882A3 (de) |
IL (1) | IL157504A0 (de) |
MX (1) | MXPA03010278A (de) |
NZ (1) | NZ527687A (de) |
WO (1) | WO2002091997A2 (de) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
HUP0302278A3 (en) * | 1999-04-15 | 2011-01-28 | Pro Virus | Treatment of neoplasms with viruses |
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
US7122182B2 (en) * | 2001-05-11 | 2006-10-17 | Wellstat Biologics Corporation | Oncolytic virus therapy |
US7615209B2 (en) | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
IL145397A0 (en) * | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
US20050214266A1 (en) * | 2004-03-12 | 2005-09-29 | Oncolytics Biotech Inc. | Combination of transplantation and oncolytic virus treatment |
CA2577692C (en) * | 2004-08-20 | 2014-05-06 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
WO2007099401A2 (en) * | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
US20070077231A1 (en) | 2005-09-30 | 2007-04-05 | Contag Christopher H | Immune effector cells pre-infected with oncolytic virus |
WO2008009115A1 (en) * | 2006-07-18 | 2008-01-24 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
WO2008144067A1 (en) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Methods and compositions for treatment of cancer using oncolytic rsv activity |
CA2706750A1 (en) * | 2007-11-27 | 2009-06-04 | Ottawa Health Research Institute | Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
WO2010020247A1 (en) * | 2008-08-22 | 2010-02-25 | Reapplix Aps | Multilayered blood product |
WO2010080909A1 (en) * | 2009-01-08 | 2010-07-15 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
CA2689707A1 (en) | 2009-11-16 | 2011-05-16 | Jean-Simon Diallo | Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening |
US8859256B2 (en) | 2011-10-05 | 2014-10-14 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
US20140087362A1 (en) | 2012-03-16 | 2014-03-27 | Aladar A. Szalay | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
WO2013158265A1 (en) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
CA3203273A1 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
HRP20230659T1 (hr) | 2015-01-26 | 2023-10-13 | Ottawa Hospital Research Institute | Sastavi i metode za osjetljivost na viruse |
GB201504251D0 (en) | 2015-03-13 | 2015-04-29 | Virttu Biolog Ltd And University Of Sheffield The | Oncolytic herpes simplex virus infected cells |
CN109715657A (zh) | 2016-04-15 | 2019-05-03 | 高山免疫科学股份有限公司 | Cd80变体免疫调节蛋白及其用途 |
US10882914B2 (en) | 2016-04-15 | 2021-01-05 | Alpine Immune Sciences, Inc. | ICOS ligand variant immunomodulatory proteins and uses thereof |
CA3032120A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US11517598B2 (en) | 2016-10-03 | 2022-12-06 | Ottawa Hospital Research Institute | Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic RNA viruses |
KR20190099194A (ko) | 2016-10-20 | 2019-08-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 분비가능한 변이체 면역조절 단백질 및 조작된 세포 치료 |
WO2018148462A1 (en) | 2017-02-09 | 2018-08-16 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
EP3596116B1 (de) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1-variante immunmodulatorische proteine und verwendungen davon |
CN110809581A (zh) | 2017-03-16 | 2020-02-18 | 高山免疫科学股份有限公司 | Pd-l2变体免疫调节蛋白及其用途 |
NZ756395A (en) | 2017-03-16 | 2024-01-26 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
SG11202003078VA (en) | 2017-10-18 | 2020-05-28 | Alpine Immune Sciences Inc | Variant icos ligand immunomodulatory proteins and related compositions and methods |
KR102662837B1 (ko) | 2018-06-04 | 2024-05-03 | 카리디 바이오테라퓨틱스, 인크. | 바이러스 치료법의 강화를 위한 세포-기반 비히클 |
US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
EP3844276A2 (de) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Manipulierte immunstimulierende bakterienstämme und verwendungen davon |
CN113271955A (zh) | 2018-11-06 | 2021-08-17 | 卡利迪生物治疗有限公司 | 用于细胞介导的溶瘤病毒疗法的增强的系统 |
JP2022511735A (ja) | 2018-11-21 | 2022-02-01 | インダプタ セラピューティクス インコーポレイテッド | ナチュラルキラー(nk)細胞サブセットの増大のための方法ならびに関連する組成物および方法 |
EP3887394A2 (de) | 2018-11-30 | 2021-10-06 | Alpine Immune Sciences, Inc. | Cd86-variante immunmodulatorische proteine und verwendungen davon |
KR20220004959A (ko) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아 |
EP4139439A1 (de) | 2020-04-22 | 2023-03-01 | Indapta Therapeutics, Inc. | Zusammensetzungen natürlicher killerzellen (nk) und verfahren zur erzeugung davon |
WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5126132A (en) * | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
DK0696326T5 (da) * | 1993-04-30 | 2003-07-14 | Wellstat Biologics Corp | Anvendelse af NDV til fremstilling af et medikament til behandling af cancer |
US5595739A (en) * | 1993-05-07 | 1997-01-21 | Abbott Laboratories | Hepatitis B virus mutants, reagents and methods for detection |
US6207147B1 (en) * | 1996-10-11 | 2001-03-27 | The Regents Of The University Of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
US5910434A (en) * | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
NZ550147A (en) * | 1997-10-09 | 2008-09-26 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
US6177076B1 (en) * | 1997-12-09 | 2001-01-23 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
WO1999045783A1 (en) * | 1998-03-12 | 1999-09-16 | The Trustees Of The University Of Pennsylvania | Producer cells for replication selective viruses in the treatment of malignancy |
US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
HUP0302278A3 (en) * | 1999-04-15 | 2011-01-28 | Pro Virus | Treatment of neoplasms with viruses |
JP3639772B2 (ja) * | 1999-06-30 | 2005-04-20 | キヤノン株式会社 | 情報処理装置および印刷システムおよび印刷制御方法およびコンピュータが読み出し可能なプログラムを格納した記憶媒体 |
ES2320239T3 (es) | 1999-09-17 | 2009-05-20 | Wellstat Biologics Corporation | Virus oncolitico. |
US6270147B1 (en) * | 2000-01-07 | 2001-08-07 | Daimlerchrysler Corporation | Drive arrangement for a power liftgate including clutching mechanism |
AU2001279264B2 (en) * | 2000-06-26 | 2005-04-28 | University Of Ottawa | Purging of cells using viruses |
US7122182B2 (en) * | 2001-05-11 | 2006-10-17 | Wellstat Biologics Corporation | Oncolytic virus therapy |
-
2002
- 2002-05-09 US US10/142,405 patent/US7122182B2/en not_active Expired - Fee Related
- 2002-05-09 AT AT02725980T patent/ATE500808T1/de not_active IP Right Cessation
- 2002-05-09 CN CNB028097009A patent/CN1332712C/zh not_active Expired - Fee Related
- 2002-05-09 IL IL15750402A patent/IL157504A0/xx not_active IP Right Cessation
- 2002-05-09 AU AU2002256510A patent/AU2002256510B2/en not_active Ceased
- 2002-05-09 DE DE60239394T patent/DE60239394D1/de not_active Expired - Lifetime
- 2002-05-09 NZ NZ527687A patent/NZ527687A/en not_active IP Right Cessation
- 2002-05-09 EP EP02725980A patent/EP1385466B1/de not_active Expired - Lifetime
- 2002-05-09 WO PCT/US2002/014642 patent/WO2002091997A2/en active IP Right Grant
- 2002-05-09 CA CA2442648A patent/CA2442648C/en not_active Expired - Fee Related
- 2002-05-09 JP JP2002588916A patent/JP4916641B2/ja not_active Expired - Fee Related
- 2002-05-09 MX MXPA03010278A patent/MXPA03010278A/es active IP Right Grant
- 2002-05-09 HU HU0400882A patent/HUP0400882A3/hu unknown
-
2005
- 2005-05-05 US US11/122,690 patent/US7595042B2/en not_active Expired - Fee Related
-
2009
- 2009-03-26 US US12/412,035 patent/US8137663B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050208024A1 (en) | 2005-09-22 |
CN1514688A (zh) | 2004-07-21 |
EP1385466A4 (de) | 2005-10-12 |
US20090180994A1 (en) | 2009-07-16 |
HUP0400882A2 (hu) | 2004-07-28 |
CA2442648A1 (en) | 2002-11-21 |
EP1385466B1 (de) | 2011-03-09 |
US7122182B2 (en) | 2006-10-17 |
AU2002256510B2 (en) | 2007-08-30 |
CN1332712C (zh) | 2007-08-22 |
JP4916641B2 (ja) | 2012-04-18 |
JP2004521938A (ja) | 2004-07-22 |
US20030077819A1 (en) | 2003-04-24 |
EP1385466A2 (de) | 2004-02-04 |
NZ527687A (en) | 2005-10-28 |
CA2442648C (en) | 2012-10-16 |
ATE500808T1 (de) | 2011-03-15 |
HUP0400882A3 (en) | 2011-01-28 |
MXPA03010278A (es) | 2004-12-06 |
WO2002091997A2 (en) | 2002-11-21 |
IL157504A0 (en) | 2004-03-28 |
WO2002091997A3 (en) | 2003-03-13 |
US8137663B2 (en) | 2012-03-20 |
US7595042B2 (en) | 2009-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE500808T1 (de) | Onkolytische virustherapie | |
NO20026044L (no) | Behandling av humant papillomavirus | |
ES2187798T3 (es) | Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. | |
BR9912653A (pt) | Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal | |
DK184186A (da) | Terapeutisk praeparat til behandling af virussygdomme | |
DE60026554D1 (de) | Onkolytisches vesicular stomatitis virus | |
CY1105818T1 (el) | Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου | |
TR200001891T2 (tr) | ASPB28- İnsan ensülini ve kullanımı. | |
MY117892A (en) | Therapeutic compounds | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
AP9801286A0 (en) | Therapeutic compounds. | |
ATE185274T1 (de) | Therapeutisches mittel gegen drohenden abortus | |
ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
ATE295159T1 (de) | Bupropion zur behandlung von viralen erkrankungen | |
EA199800770A1 (ru) | Лекарственный препарат для терапевтического лечения вирусного гепатита | |
WO2001070951A3 (de) | Mittel zur diagnose und therapie viraler erkrankungen | |
SG165996A1 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
DE69803052D1 (de) | Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt | |
DE60002172T2 (de) | Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopenten-1-methanol in hbv | |
SU1565027A1 (ru) | Инактиватор вируса западного нила | |
DK1173481T3 (da) | Inaktiverede cytokiner ril immunisering | |
DK0788355T3 (da) | Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme | |
HRP20030701A2 (en) | Natural antibodies active against hiv virus | |
RU99122488A (ru) | Способ лечения рака эндометрия | |
UA37445A (uk) | Протизапальний засіб |